Surrozen reports Phase 1a SZN-043 data: safe, target engagement, liver function effects; Phase 1b starts

Surrozen, Inc./DE

Phase 1a enrolled 48 subjects (40 healthy, 8 cirrhotic); doses 0.5-3 mg/kg IV; no serious adverse events.
Demonstrated target engagement via transient ALP increases and Wnt pathway activation by methacetin breath test.
In cirrhotic patients, dose-dependent pharmacodynamic effect and improvement in liver function via HepQuant test observed.
Initiating Phase 1b proof-of-concept trial in severe alcohol-associated hepatitis; data expected first half 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.